Gilead price target raised to $105 from $95 at Piper Sandler
The Fly

Gilead price target raised to $105 from $95 at Piper Sandler

Piper Sandler raised the firm’s price target on Gilead (GILD) to $105 from $95 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 earnings with a high quality top- and bottom-line beat. Altogether, the commercial business remains strong with the HIV business growing at a healthy clip and improving visibility into near-term growth drivers like lenacapavir and anito-cel, Piper adds.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App